General Introduction

Migraine is a chronic disorder characterized by headache attacks of moderate to severe intensity, unilateral location, aggravation by routine physical activity and is also associated with nausea and/or photophobia and phonophobia. Attacks usually last for several hours, but can last 2-3 days in adults. Women are more likely than men to suffer from migraines and migraines can run in families. Migraine attacks strongly interfere with daily activities, and if attacks are frequent the condition can be very debilitating and cause a major negative effect on a patient’s life. Primary headaches, (headaches without an identifiable underlying cause), affect about 46% of people globally and about one fourth of this number are migraine sufferers.

Currently there is no allopatic cure for migraines. Although acute attacks can be suppressed by medications (e.g. triptans), these cause many side effects, and overuse can lead to drug-induced headaches. Drugs designed for the prevention of acute attacks are known to have limitations and they do not work for many patients.

History

The patient - female, 57 y.o. - had been suffering from migraines for most of her life, and reported that attacks occurred 2-3 times a month. Her symptoms included severe pain, nausea, photophobia and vision impairment. Over the years she used various analgesic medications, starting with Aspirin and then progressing to stronger substances, such as Imigran (Sumatriptan). Around 20 years ago she had to receive Sumatriptan through injection from a doctor. However owing to the increased costs at the time she changed to taking Formigran (naratriptan hydrochlorite).

coMra Treatment

The patient did Universal 1, 1-2 times a day, daily for four weeks.

No other therapy was applied and no medication was used.

Results

The patient reported no migraine attacks for the 3 months after the end of the treatment course. The attacks subsequently returned, but these were less severe, as well as less frequent than before. The reduction in severity and frequency has lasted until the date of her last report, that is, 2 years after the treatment.

Case provided by: Oliver Müller
Country: United Kingdom